Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: A randomised, controlled phase 3 trial

Multiple Sclerosis Journal

Volumn 20, Issue 6, 2014, Pages 705-716

  Vermersch, Patrick ^a   Czlonkowska, Anna ^b   Grimaldi, Luigi Me ^c   Confavreux, Christian ^d   Comi, Giancarlo ^e   Kappos, Ludwig ^f   Olsson, Tomas P ^g   Benamor, Myriam ^h   Bauer, Deborah ^h   Truffinet, Philippe ^h   Church, Meg ⁱ   Miller, Aaron E ^j   Wolinsky, Jerry S ^k   Freedman, Mark S ^l   O'Connor, Paul ^m  

^a UNIV LILLE   (France)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^c Fondazione Istituto San Raffaele G Giglio di Cefalù   (Italy)

^d UNIVERSITÉ LYON 1   (France)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g KAROLINSKA INSTITUTE   (Sweden)

^h SANOFI   (France)

ⁱ Fishawack Communications   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^l OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^m ST MICHAEL'S HOSPITAL   (Canada)

more..

Author keywords

acute relapsing; disease modifying therapy; Multiple sclerosis; pharmacologic therapy; relapsing remitting; teriflunomide

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BETA1A INTERFERON; TERIFLUNOMIDE; TRIACYLGLYCEROL LIPASE; BETA INTERFERON; CROTONIC ACID DERIVATIVE; IMMUNOLOGICAL ADJUVANT; TOLUIDINE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANNUALISED RELAPSE RATE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BREAST DISEASE; CELLULITIS; CHOLECYSTITIS; CHRONIC SINUSITIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EAR DISEASE; EXPANDED DISABILITY STATUS SCALE; EYE DISEASE; EYE EDEMA; FATIGUE IMPACT SCALE; FEMALE; FEVER; FLU LIKE SYNDROME; FOREARM FRACTURE; GALLBLADDER DISEASE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HEADACHE; HEMOLYSIS; HUMAN; INNER EAR DISEASE; ISCHEMIC OPTIC NEUROPATHY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; MICROPIPETTE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OPTIC NEURITIS; OUTCOME ASSESSMENT; PARESTHESIA; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERIANAL ABSCESS; PHASE 3 CLINICAL TRIAL; POLYP; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SUPRAVENTRICULAR TACHYCARDIA; THORAX DISEASE; TIBIA FRACTURE; TREATMENT RESPONSE; TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUBERCULOSIS; URTICARIA; UTERINE CERVICITIS; UTERUS SARCOMA; VASCULAR DISEASE; VERTIGO; AGED; CLINICAL TRIAL; DISEASE COURSE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENT DISEASE; TREATMENT OUTCOME; BALANCE DISORDER; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEPRESSION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPEPSIA; HYPERTRANSAMINASEMIA; INCIDENCE; INSOMNIA; INTERVERTEBRAL DISK HERNIA; LIMB PAIN; NAUSEA; PANIC; TREATMENT WITHDRAWAL; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; UTERINE CERVIX DISEASE; UTERINE CERVIX POLYP; VEIN OCCLUSION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; CROTONATES; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; TOLUIDINES; TREATMENT OUTCOME;

EID: 84897022266     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513507821     Document Type: Article

References (25)

1. Allison AC, Eugui EM. Inhibitors of de novo purine and pyrimidine synthesis as immunosuppressive drugs. Transplant Proc. 1993 ; 25: 8-18
2. Silva HT, Morris RE. Leflunomide and malononitriloamides. Expert Opin Investig Drugs. 1997 ; 6: 51-64
3. Li L, Liu J, Ringheim G, et al. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells (P938). Mult Scler. 2011 ; 17: S422
4. Merrill JE, Hanak S, Pu SF, et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol. 2009 ; 256: 89-103
5. Petty M, Lee L, Ying X. Teriflunomide treatment reduces infiltration of macrophages, T cells and B cells and increases survival of oligodendrocytes in the spinal cord of the Dark Agouti rat model of experimental allergic encephalomyelitis. Neurology. 74: A415
6. Ringheim G, Lee L, Laws-Ricker L, et al. Teriflunomide attenuates immunopathological changes in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. Mult Scler. 2011 ; 17: S187
7. Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS: Teriflunomide. Clin Immunol. 2012 ; 142: 49-56
8. Cherwinski HM, Cohn RG, Cheung P, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther. 1995 ; 275: 1043-1049
9. Linke SP, Clarkin KC, Di Leonardo A, et al. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 1996 ; 10: 934-947
10. Silva HT, Cao W, Shorthouse R, et al. Mechanism of action of leflunomide: In vivo uridine administration reverses its inhibition of lymphocyte proliferation. Transplant Proc. 1996 ; 28: 3082-3084
11. Press Release: Genzyme presents second phase III study of once-daily oral Aubagio (teriflunomide) confirming significant impact on disability. Available at: http://www.marketwatch.com/story/genzyme-presents-second-phase-iii-study-of- once-daily-oral-aubagior-teriflunomide-confirming-significant-impact-on- disability-2012-10-12 (2012, accessed 22 April 2013).
12. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011 ; 365: 1293-1303
13. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 ; 58: 840-846
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452
15. Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: Initial validation of the fatigue impact scale. Clin Infect Dis. 1994 ; 18: S79 - S83
16. Frith J, Newton J. Fatigue Impact Scale. Occup Med (Lond). 2010 ; 60: 159
17. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004 ; 2: 12
18. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998 ; 352: 1498-1504
19. O'Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006 ; 66: 894-900
20. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002 ; 59: 1496-1506
21. Francis GS, Grumser Y, Alteri E, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: Incidence and clinical significance. Drug Saf. 2003 ; 26: 815-827
22. Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: Safety and efficacy results up to 8.5 years. Mult Scler. 2012 ; 18: 1278-1289
23. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): A multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011 ; 18: 69-77
24. Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract. 2007 ; 61: 1922-1930
25. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012 ; 18: 527-539